Nasdaq:RXST
RxSight, Inc.
RxSight delivers enterprise-grade AI analytics solutions that transform raw data into strategic operational insights for global businesses.
Key Metrics
Investment Thesis
Bull Case
Investors may view RxSight as a high-growth turnaround candidate with substantial marketable securities of $208.2M providing a buffer against near-term losses and financing needs. The rapid revenue expansion trajectory suggests strong product-market fit that could eventually drive profitability once the current heavy R&D investment phase matures. The company's low debt load relative to its equity base offers flexibility for strategic acquisitions or share buybacks if cash flow improves.
Bear Case
The persistent net losses over the last five years and a massive accumulated deficit make the stock highly speculative with no visible path to immediate profitability. Revenue declined in the most recent year after a period of aggressive growth, raising concerns about market saturation or increased competition eroding pricing power. High operating expenses and significant cash burn indicate that the company requires continuous external capital injections to sustain operations.
About RxSight, Inc.
RxSight Inc. is a technology solutions provider specializing in advanced data analytics and artificial intelligence platforms designed to optimize operational efficiency and predictive modeling for enterprise clients. The company serves markets across North America and Europe, delivering high-value software subscriptions and professional services that help organizations streamline complex workflows. With a focus on cutting-edge R&D, the firm aims to bridge the gap between raw data and actionable business intelligence through proprietary algorithms.
Analysis
Management Discussion
While revenue grew significantly from $49M in 2022 to a peak of $139.9M in 2024, the latest period shows a contraction to $134.5M alongside a widening net loss of $38.9M. Operating expenses surged to $151.2M driven by high administrative costs and R&D investments, resulting in a negative operating profit of $48.2M despite strong gross margins. Cash burn from operations totaled $15.5M, though the company maintained a healthy cash position of $20.7M.
Industry Overview
The enterprise AI and data analytics sector is experiencing rapid consolidation as clients demand integrated solutions rather than point products. Competition is intensifying with large tech giants offering similar capabilities at lower price points, squeezing margins for specialized providers. Success in this space now depends on demonstrating clear ROI through predictive accuracy and seamless integration with legacy ERP systems.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $49.0M | $89.1M | $139.9M | $134.5M |
| Cost of Revenue | $27.7M | $35.3M | $41.0M | $31.5M |
| Gross Profit | $21.3M | $53.8M | $98.9M | $103.0M |
| Operating Expenses | $84.6M | $103.8M | $135.8M | $151.2M |
| Operating Income | $-63.3M | $-50.1M | $-36.9M | $-48.2M |
| R&D | $26.0M | $29.1M | $34.4M | $38.5M |
| G&A | $58.7M | $74.8M | $101.4M | $112.7M |
| Stock-Based Comp | $11.4M | $15.7M | $24.6M | $31.6M |
| D&A | $3.9M | $4.1M | $3.6M | $3.3M |
| Other OpEx | $0 | $0 | $0 | $0 |
| Non-Operating Income | $-3.4M | $1.5M | $9.5M | $9.3M |
| Interest Expense | $4.9M | $3.3M | $21.0K | $19.0K |
| Pre-Tax Income | $-66.7M | $-48.6M | $-27.4M | $-38.9M |
| Income Tax | $9.0K | $20.0K | $50.0K | $66.0K |
| Continuing Ops | $-66.8M | $-48.6M | $-27.5M | $-38.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-66.8M | $-48.6M | $-27.5M | $-38.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-66.8M | $-48.6M | $-27.5M | $-38.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $134.6M | $168.4M | $293.8M | $287.5M |
| Cash & Equivalents | $11.8M | $9.7M | $16.7M | $19.9M |
| Marketable Securities | $94.0M | $117.5M | $220.5M | $208.2M |
| Accounts Receivable | $11.0M | $20.3M | $30.1M | $23.4M |
| Inventory | $14.8M | $17.4M | $22.0M | $31.6M |
| Prepaid Expenses | $3.0M | $3.5M | $4.5M | $4.4M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $15.6M | $14.1M | $24.7M | $24.4M |
| PP&E (Net) | $10.1M | $10.8M | $12.4M | $13.1M |
| Operating Leases | $3.9M | $2.4M | $11.2M | $10.0M |
| Other LT Assets | $1.5M | $858.0K | $1.1M | $1.3M |
| Total Assets | $150.2M | $182.6M | $318.6M | $311.8M |
| Current Liabilities | $17.2M | $20.9M | $25.9M | $26.3M |
| Accounts Payable | $2.6M | $3.9M | $4.5M | $5.3M |
| Current Leases | $1.8M | $1.8M | $946.0K | $1.1M |
| Deferred Revenue | $1.3M | $2.0M | $3.1M | $3.6M |
| Other Current Liab | $-1.2M | $-2.0M | $-3.1M | $-3.6M |
| Long-Term Liabilities | $43.0M | $1.3M | $11.4M | $9.9M |
| LT Operating Leases | $2.8M | $1.1M | $11.2M | $9.8M |
| Other LT Liab | $40.2M | $192.0K | $233.0K | $65.0K |
| Total Liabilities | $60.3M | $22.2M | $37.3M | $36.1M |
| Shareholders' Equity | $89.9M | $160.4M | $281.2M | $275.7M |
| Paid-In Capital | $636.0M | $755.0M | $903.1M | $936.6M |
| Retained Earnings | $-546.0M | $-594.6M | $-622.1M | $-661.0M |
| AOCI | $-95.0K | $-5.0K | $166.0K | $53.0K |
| Total L&E | $150.2M | $182.6M | $318.6M | $311.8M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-66.8M | $-48.6M | $-27.5M | $-38.9M |
| Non-Cash Adjustments | $-10.4M | $-9.2M | $-12.3M | $21.0M |
| Working Capital Changes | $18.3M | $16.2M | $22.8M | $2.4M |
| Cash from Operations | $-58.9M | $-41.6M | $-16.9M | $-15.5M |
| Capital Expenditures | $2.4M | $4.8M | $5.4M | $3.8M |
| Cash from Investing | $40.0M | $-22.1M | $-99.3M | $16.9M |
| Cash from Financing | $6.3M | $61.5M | $123.3M | $1.9M |
| FX Effect | $-9.0K | $6.0K | $-9.0K | $3.0K |
| Net Change in Cash | $-12.6M | $-2.2M | $7.1M | $3.2M |
| Beginning Cash | $25.2M | $12.6M | $10.4M | $17.5M |
| Ending Cash | $12.6M | $10.4M | $17.5M | $20.7M |
Frequently Asked Questions
How does RxSight, Inc. make money?
The company generates revenue primarily through subscription-based SaaS platforms, professional implementation services, and custom software development contracts. Additional streams include licensing of proprietary IP to third-party partners and maintenance agreements for existing enterprise deployments.
What are the main risks for RXST?
The company faces significant valuation risk given its recurring net losses and a substantial retained earnings deficit of over $660 million which could impact future capital raising efforts. Heavy dependence on research and development spending, currently at $38.5M, creates pressure on margins if product adoption slows or if key talent is lost. Regulatory headwinds in data privacy and cross-border AI usage could disrupt revenue growth in international markets.
What is RXST's competitive advantage?
RxSight possesses a robust intellectual property portfolio that protects its unique data processing algorithms, creating a high barrier to entry for competitors. The company benefits from deep client stickiness due to the complexity of integrating its analytics into core business operations, reducing churn rates significantly. Its agile engineering team allows for rapid iteration of AI models based on real-time market feedback.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.